Ads
related to: Stelara- Patient Resources
Information About Injecting
Cost Support and More
- About STELARA®
Information on Getting Started
Learn More About STELARA® Today
- Save on STELARA®
Eligible Patients pay $5 copay/dose
2020 additional requirements apply
- Cost Support Information
Learn About Cost Support Options
View Support Program Info.
- Patient Resources
Search results
J&J’s Tremfya superior to Stelara in Phase II/III Chron’s disease trials
Clinical Trials Arena via Yahoo Finance· 2 days agoJohnson and Johnson’s Johnson and Johnson’s Tremfya (guselkumab) was superior to its Stelara...
Lilly (LLY) Hits Record High on Crohn's Disease Study Data
Zacks via Yahoo Finance· 2 days agoHowever, the results were mixed when the results when the Lilly drug was pitted against J&J’s JNJ...
IBD Stock Of The Day Eli Lilly Breaks Out On Its Way To A Record High
Investor's Business Daily· 2 days agoIn the patients who worsened while taking a prior biologic, 43.4% of mirikizumab patients entered...
J&J’s Tremfya meets endpoints in Phase III ulcerative colitis trial
Clinical Trials Arena via Yahoo Finance· 3 days agoJ&J’s Tremfya is expected to be the successor to the company’s IL-12/IL-23 inhibitor Stelara...
Earnings call: Alvotech raises 2024 guidance amid strong biosimilar push By Investing.com
Investing.com· 19 hours agoAlvotech, a global biopharmaceutical company, has reported a robust first quarter in 2024, with...
Finding the Best Psoriasis Treatment: How I Got Psoriasis Relief
Verywell Health via Yahoo News· 3 days agoLiving Life With Psoriasis As with many chronic illnesses, psoriasis cannot be cured, but it can be...
Guselkumab Continues Winning Streak in Crohn's Disease
MedPage Today· 2 days agoInduction and maintenance treatment with guselkumab (Tremfya) demonstrated its safety and efficacy...
Johnson & Johnson shares maintain outperform rating at RBC on TREMFYA potential By Investing.com
Investing.com· 2 days agoOn Wednesday, RBC (TSX:RY) Capital maintained its positive stance on Johnson & Johnson (NYSE:JNJ),...
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease...
The Parsons Sun· 7 days ago- AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD)
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 3 days agoTeva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk ...
Ads
related to: Stelara